Arvinas Inc(ARVN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:22 AM ET (Korea 9/11 20:22)
Full metrics table
| Index | RUT | P/E | 54.3 | EPS (ttm) | 0.16 | Insider Own | 10.52% | Shs Outstand | 65.3M | Perf Week | -9.18% |
| Market Cap | 0.57B | Forward P/E | - | EPS next Y | -8053.92% | Insider Trans | -0.87% | Shs Float | 58.5M | Perf Month | -3.11% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -0.87 | Inst Own | 79.13% | Short Float | 6.92% | Perf Quarter | 24.79% |
| Income | 0.01B | P/S | 1.8 | EPS this Y | 96.43% | Inst Trans | 1.14% | Short Ratio | 5.34 | Perf Half Y | -35.39% |
| Sales | 0.32B | P/B | 1.01 | EPS next 5Y | - | ROA | 1.17% | Short Interest | 4.05M | Perf YTD | -26.56% |
| Book/sh | 8.61 | P/C | 1 | EPS past 3/5Y | 40.13% 17.7% | ROE | 1.59% | 52W High | -39.97% ($14.51) | Perf Year | 11.24% |
| Cash/sh | 8.69 | P/FCF | - | Sales past 3/5Y | 25.96% 64.5% | ROIC | 1.64% | 52W Low | 24.96% ($6.97) | Perf 3Y | -68.46% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 119.57% | Gross Margin | 95.64% | Volatility(W/M) | 3.98% 3.53% | Perf 5Y | -91.03% |
| Dividend TTM | - | EV/Sales | 0.03 | Sales Y/Y TTM | -15.05% | Oper. Margin | -4.01% | ATR (14) | 0.36 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 7.91 | EPS Q/Q | 407.54% | Profit Margin | 2.94% | RSI (14) | 43.78 | Recom | 2.31 |
| Dividend Gr. 3/5Y | - | Current Ratio | 7.91 | Sales Q/Q | 1014.73% | SMA20 | -5.59% ($9.23) | Beta | 1.79 | Target Price | $13.93 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/4 | SMA50 | -0.02% ($8.71) | Rel Volume | 1.02 | Prev Close | $8.76 |
| Employees | 246 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | 789.66% 311.31% | SMA200 | -17.01% ($10.5) | Avg Volume(3M) | 0.76M | Price | $8.71 |
| IPO | 2018/9/27 | Option/Short | Yes/Yes | Trades | 10160 | Volume | 776,211 | Change | -0.57% |
Company
ARVN is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A clinical-stage biopharmaceutical company developing targeted therapeutics based on a PROTAC platform that leverages the body's natural protein degradation system to eliminate disease-causing proteins. Building on its groundbreaking targeted protein degradation (TPD) technology, the company focuses on developing treatments for breast cancer and neurodegenerative diseases—conditions that have historically been difficult to address with traditional small-molecule compounds—and is validating the potential of its pipeline through multiple strategic partnerships.
Over the past 1 year, on the lower side
40% below its 1-year high.
ARVN has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by +96.4% this year.
Tap to view numbers
The price looks about right
Trading at 54.3 times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -68.5% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 79.1%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
XPH 0.01%
PILL 0.01%
BBC 0.01%
CANC 0.00%
SMIZ 0.00%It ranks #4 in the industry
Based on market cap of $570M.
ARVN $570M PER 54.3
VRTX $130B PER 29.9
REGN $82B PER 19.6
ARGX $62B PER 37.5
FAQ
What kind of company is ARVN?
ARVN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ARVN?
The market cap of ARVN is approximately $570M, ranking 3,117 within its sector.
What is the P/E ratio of ARVN?
ARVN has a P/E ratio of approximately 54.3x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for ARVN?
ARVN has recorded a 52-week high of $14.51 and a low of $6.97.
